CDIO · Cardio Diagnostics Holdings, Inc.

Robert Philibert a Director and Chief Medical Officer (CMO) of the registrant, is the direct owner of 75,676 of the securities of the registrant reported herein, owns and controls BD Holding Inc., the direct owner of 1,586,464 of the securities of the registrant reported herein, owns and controls Behavioral Diagnostics LLC, the direct owner of 14,126 of the securities of the registrant reported herein, and his spouse is the direct owner of 7,601of the securities of the registrant reported herein.

The reporting person holds the shares in an account with his spouse, the issuer's Chief Executive Officer, as joint tenants with rights of survivorship.

The reporting person's direct ownership is 128,345 shares of common stock held individually and 68,965 shares of common stock held jointly with his spouse, the issuer's Chief Executive Officer.

The reporting person holds the shares in an account with his spouse, the issuer's Chief Executive Officer, as joint tenants with rights of survivorship.

The reporting person's direct ownership is 128,345 shares of common stock held individually and 68,965 shares of common stock held jointly with his spouse, the issuer's Chief Executive Officer.

The reporting person holds the shares in an account with his spouse, the issuer's Chief Executive Officer, as joint tenants with rights of survivorship.

The reporting person's direct ownership is 128,345 shares of common stock held individually and 68,965 shares of common stock held jointly with his spouse, the issuer's Chief Executive Officer.

The reporting person holds the shares in an account with her spouse, the issuer's Chief Technology Officer, as joint tenants with rights of survivorship.

The reporting person's direct ownership is 1,586,464 shares of common stock held individually and 68,965 shares of common stock held jointly with her spouse who is the issuer's Chief Technology Officer.

Robert Philibert a Director and Chief Medical Officer (CMO) of the registrant, is the direct owner of 75,676 of the securities of the registrant reported herein, owns and controls BD Holding Inc., the direct owner of 1,586,464 of the securities of the registrant reported herein, owns and controls Behavioral Diagnostics LLC, the direct owner of 14,126 of the securities of the registrant reported herein, and his spouse is the direct owner of 7,601of the securities of the registrant reported herein.

The reporting person holds the shares in an account with her spouse, the issuer's Chief Technology Officer, as joint tenants with rights of survivorship.

The reporting person's direct ownership is 1,586,464 shares of common stock held individually and 68,965 shares of common stock held jointly with her spouse, the issuer's Chief Technology Officer.

The reporting person holds the shares in an account with her spouse, the issuer's Chief Technology Officer, as joint tenants with rights of survivorship.

The reporting person's direct ownership is 1,586,464 shares of common stock held individually and 68,965 shares of common stock held jointly with her spouse who is the issuer's Chief Technology Officer.

Each RSU is the economic equivalent of one share of Cardio Diagnostics Holdings, Inc. common stock. On March 31, 2024, $12,500 in value of RSUs vested and were settled at the price of $1.42, which was the closing price of the Company Common Stock on the vesting date. The settlement shares are reflected in Table I.

The RSUs were granted pursuant to the Issuers 2022 Equity Incentive Plan.

Each RSU is the economic equivalent of one share of Cardio Diagnostics Holdings, Inc. common stock. On March 31, 2024, $12,500 in value of RSUs vested and were settled at the price of $1.42, which was the closing price of the Company Common Stock on the vesting date. The settlement shares are reflected in Table I.

Each RSU is the economic equivalent of one share of Cardio Diagnostics Holdings, Inc. common stock. On March 31, 2024, $12,500 in value of RSUs vested and were settled at the price of $1.42, which was the closing price of the Company Common Stock on the vesting date. The settlement shares are reflected in Table I.

The RSUs were granted pursuant to the Issuers 2022 Equity Incentive Plan.

On January 23, 2024, the reporting person was awarded $50,000 in value of RSUs, $12,500 in value of which vested on March 31, 2024. Subject to continued service with the Issuer on the vesting date, the RSUs will continue to vest $12,500 in value on June 30, 2024, $12,500 in value on September30, 2024 and $12,500 in value on December 31, 2024, based on the closing price of the Issuers common stock on the applicable vesting date.

Each RSU is the economic equivalent of one share of Cardio Diagnostics Holdings, Inc. common stock. On March 31, 2024, $12,500 in value of RSUs vested and were settled at the price of $1.42, which was the closing price of the Company Common Stock on the vesting date. The settlement shares are reflected in Table I.

The RSUs were granted pursuant to the Issuers 2022 Equity Incentive Plan.

On January 23, 2024, the reporting person was awarded $50,000 in value of RSUs, $12,500 in value of which vested on March 31, 2024. Subject to continued service with the Issuer on the vesting date, the RSUs will continue to vest $12,500 in value on June 30, 2024, $12,500 in value on September30, 2024 and $12,500 in value on December 31, 2024, based on the closing price of the Issuers common stock on the applicable vesting date.

Represents the settlement of restricted stock units (RSUs) that vested on December 31, 2023 through the issuance of shares of Common Stock.

Represents the settlement of restricted stock units (RSUs) that vested on March 31, 2024 through the issuance of shares of Common Stock.

Each RSU is the economic equivalent of one share of Cardio Diagnostics Holdings, Inc. common stock. On March 31, 2024, $12,500 in value of RSUs vested and were settled at the price of $1.42, which was the closing price of the Company Common Stock on the vesting date. The settlement shares are reflected in Table I.

The RSUs were granted pursuant to the Issuers 2022 Equity Incentive Plan.

On January 23, 2024, the reporting person was awarded $50,000 in value of RSUs, $12,500 in value of which vested on March 31, 2024. Subject to continued service with the Issuer on the vesting date, the RSUs will continue to vest $12,500 in value on June 30, 2024, $12,500 in value on September30, 2024 and $12,500 in value on December 31, 2024, based on the closing price of the Issuers common stock on the applicable vesting date.

Represents the settlement of restricted stock units (RSUs) that vested on March 31, 2024 through the issuance of shares of Common Stock.

Represents the settlement of restricted stock units (RSUs) that vested on March 31, 2024 through the issuance of shares of Common Stock.